Trial Profile
To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine (Lastacaft)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Alcaftadine (Primary)
- Indications Allergic conjunctivitis; Rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms OAT-PIT
- 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 Mar 2013 New trial record